ChromaDex announces $62 million ingredient agreement with 5LINX

In California, ChromaDex announced it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX, which it describes as one of the largest and fastest-growing direct marketing companies in the world.

The agreement gives 5LINX marketing rights for ChromaDex’s recently launched patented NIGAGEN Nicotinamide Riboside for use in dietary supplements exclusively in the network marketing sales channel in the United States, Canada and Philippines.  5LINX was also granted marketing rights for ChromaDex’s recently launched patented PURENERGY for use in dietary supplements in the same three companies.

More on the story.